Belite Bio to Host Webcast on November 12, 2024, to Discuss Third Quarter 2024 Financial Results
Belite Bio (NASDAQ: BLTE) announced it will host a webcast on November 12, 2024 at 4:30 p.m. Eastern Time to discuss its third quarter 2024 financial results and provide a business update. The clinical-stage biopharmaceutical company, which focuses on developing novel therapeutics for degenerative retinal diseases, will make the webcast available through their website. A replay will be accessible for approximately 90 days following the event.
Belite Bio (NASDAQ: BLTE) ha annunciato che ospiterà un webcast il 12 novembre 2024 alle 16:30 ora orientale per discutere i risultati finanziari del terzo trimestre 2024 e fornire un aggiornamento aziendale. La società biofarmaceutica in fase clinica, che si concentra sullo sviluppo di nuove terapie per le malattie retiniche degenerative, renderà disponibile il webcast attraverso il proprio sito web. Una registrazione sarà accessibile per circa 90 giorni dopo l'evento.
Belite Bio (NASDAQ: BLTE) anunció que llevará a cabo un webcast el 12 de noviembre de 2024 a las 4:30 p.m. hora del este para discutir sus resultados financieros del tercer trimestre de 2024 y proporcionar una actualización del negocio. La empresa biofarmacéutica en etapa clínica, que se centra en el desarrollo de terapias novedosas para enfermedades degenerativas de la retina, pondrá el webcast a disposición a través de su sitio web. Una repetición estará accesible durante aproximadamente 90 días después del evento.
Belite Bio (NASDAQ: BLTE)는 2024년 11월 12일 동부 표준시 기준 오후 4:30에 2024년 3분기 재무 결과를 논의하고 비즈니스 업데이트를 제공하는 웹캐스트를 개최한다고 발표했습니다. 퇴행성 망막 질환을 위한 새로운 치료법 개발에 중점을 둔 임상 단계의 생명공학 회사는 자사 웹사이트를 통해 웹캐스트를 제공할 예정입니다. 행사가 끝난 후 약 90일 동안 다시 볼 수 있는 서비스가 제공됩니다.
Belite Bio (NASDAQ: BLTE) a annoncé qu'il organisera un webcast le 12 novembre 2024 à 16h30, heure de l'Est, pour discuter de ses résultats financiers du troisième trimestre 2024 et fournir une mise à jour sur l'entreprise. La société biopharmaceutique en phase clinique, qui se concentre sur le développement de nouvelles thérapies pour les maladies dégénératives de la rétine, mettra le webcast à disposition via son site web. Un enregistrement sera accessible pendant environ 90 jours après l'événement.
Belite Bio (NASDAQ: BLTE) gab bekannt, dass am 12. November 2024 um 16:30 Uhr Eastern Time ein Webcast stattfinden wird, um die finanziellen Ergebnisse des dritten Quartals 2024 zu besprechen und ein Update zum Unternehmen zu geben. Das biopharmazeutische Unternehmen in der klinischen Phase, das sich auf die Entwicklung neuer Therapeutika für degenerative Netzhauterkrankungen konzentriert, wird den Webcast über seine Website verfügbar machen. Eine Wiederholung wird etwa 90 Tage nach der Veranstaltung zugänglich sein.
- None.
- None.
SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it will host a webcast on Tuesday, November 12, 2024, at 4:30 p.m. Eastern Time to discuss the Company’s financial results and provide a business update for the third quarter ended September 30, 2024.
Webcast Information
Date: Tuesday, November 12, 2024
Time: 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time)
Webcast Link: https://wsw.com/webcast/cc/blte5/1423080
Webcast Link Instructions
You can join the live webcast by visiting the link above or the “Presentations & Events” section of the Company’s Investor Relations website at https://investors.belitebio.com/presentations-events/events. A replay will be available for approximately 90 days after the event.
About Belite Bio
Belite Bio is a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, such as Stargardt Disease type 1 (STGD1) and Geographic Atrophy (GA) in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite’s lead candidate, Tinlarebant, an oral therapy intended to reduce the accumulation of toxins in the eye, is currently being evaluated in a Phase 3 study (DRAGON) and a Phase 2/3 study (DRAGON II) in adolescent STGD1 subjects and a Phase 3 study (PHOENIX) in subjects with GA. For more information, follow us on Twitter, Instagram, LinkedIn, Facebook or visit us at www.belitebio.com.
Media and Investor Relations Contact:
Jennifer Wu
ir@belitebio.com
Julie Fallon
belite@argotpartners.com
FAQ
When will Belite Bio (BLTE) report Q3 2024 earnings?
How can I access Belite Bio's (BLTE) Q3 2024 earnings webcast?
How long will Belite Bio's (BLTE) Q3 2024 earnings webcast replay be available?
